Trulieve Cannabis Q2 revenue falls on Harvest deconsolidation

Trulieve Cannabis ( Delaware )

07/08/2026 11:31

Overview
US medical cannabis firm's Q2 revenue fell 10% yr/yr to $271 mln after Harvest deconsolidation
Adjusted EPS for Q2 was $0.11, with adjusted net income of $20 mln
Company announced share repurchase program up to $50 mln or 8.5 mln shares

Outlook
Company expects growth opportunities from broader cannabis rescheduling and state program expansion

Result Drivers
HARVEST DECONSOLIDATION - Co said revenue decline and net loss were primarily due to deconsolidation of Harvest operations and related equity investment
RETAIL SALES DOMINANCE - Retail sales accounted for 94% of Q2 revenue
GEORGIA EXPANSION - Co began shipment of medical cannabis products to licensed independent pharmacies in Georgia and launched new products in the state

Company press release: ID:nPn5LGpkpa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$271 mln
 
Q2 Adjusted EPS
 
$0.11
 
Q2 Loss Per Share
 
$2.10
 
Q2 Adjusted Net Income
 
$20 mln
 
Q2 Adjusted EBITDA
 
$98 mln
 
Q2 Gross Margin
 
60.00%
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Trulieve Cannabis Corp. is $20.00, about 122.2% above its August 6 closing price of $9.00

Reuters Recommended Reads
Aug 5 - Curaleaf Q2 revenue beats analyst estimates on domestic growth
Aug 5 - Verano Q2 revenue tops estimates on retail expansion
Aug 6 - Cresco Labs Q2 revenue beats estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)